AU2015263049B2 - Carboxamide derivatives - Google Patents

Carboxamide derivatives Download PDF

Info

Publication number
AU2015263049B2
AU2015263049B2 AU2015263049A AU2015263049A AU2015263049B2 AU 2015263049 B2 AU2015263049 B2 AU 2015263049B2 AU 2015263049 A AU2015263049 A AU 2015263049A AU 2015263049 A AU2015263049 A AU 2015263049A AU 2015263049 B2 AU2015263049 B2 AU 2015263049B2
Authority
AU
Australia
Prior art keywords
methyl
pyrazol
dihydro
triazole
dimethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015263049A
Other languages
English (en)
Other versions
AU2015263049A1 (en
Inventor
Mahbub AHMED
Ann-Marie D'SOUZA
Robert Alexander Pulz
Lisa Ann ROONEY
Nichola Smith
Thomas J. Troxler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2015263049A1 publication Critical patent/AU2015263049A1/en
Application granted granted Critical
Publication of AU2015263049B2 publication Critical patent/AU2015263049B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2015263049A 2014-05-14 2015-05-14 Carboxamide derivatives Ceased AU2015263049B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461993046P 2014-05-14 2014-05-14
EP14168319.3 2014-05-14
EP14168319 2014-05-14
US61/993,046 2014-05-14
PCT/IB2015/001539 WO2015177646A1 (en) 2014-05-14 2015-05-14 Carboxamide derivatives

Publications (2)

Publication Number Publication Date
AU2015263049A1 AU2015263049A1 (en) 2016-11-24
AU2015263049B2 true AU2015263049B2 (en) 2017-09-28

Family

ID=50735906

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015263049A Ceased AU2015263049B2 (en) 2014-05-14 2015-05-14 Carboxamide derivatives

Country Status (16)

Country Link
US (2) US9403833B2 (OSRAM)
EP (1) EP3143014B1 (OSRAM)
JP (1) JP6587637B2 (OSRAM)
KR (1) KR20170003667A (OSRAM)
CN (1) CN106536512B (OSRAM)
AP (1) AP2016009554A0 (OSRAM)
AR (1) AR100439A1 (OSRAM)
AU (1) AU2015263049B2 (OSRAM)
CA (1) CA2948582A1 (OSRAM)
EA (1) EA201692298A1 (OSRAM)
MX (1) MX2016014946A (OSRAM)
SG (1) SG11201609311RA (OSRAM)
TN (1) TN2016000491A1 (OSRAM)
TW (1) TW201623288A (OSRAM)
UY (1) UY36123A (OSRAM)
WO (1) WO2015177646A1 (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201946921A (zh) 2014-05-14 2019-12-16 瑞士商諾華公司 甲醯胺衍生物
US9403833B2 (en) 2014-05-14 2016-08-02 Novartis Ag Carboxamide derivatives
CN108007916B (zh) * 2017-03-16 2020-08-04 黑龙江八一农垦大学 希尔伯特黄法建立稻株氮含量的共聚焦显微拉曼测量模型
CN110749687B (zh) * 2019-04-04 2021-05-28 中山大学 一种日本血吸虫病早期诊断尿液生物标志物及筛选方法和应用
CN110038012B (zh) * 2019-05-30 2021-06-11 济南大学 具有1,2,3-三氮唑结构片段的生物碱化合物在制备促血管生成药物中的应用
DE102020116104A1 (de) 2020-06-18 2021-12-23 Charité - Universitätsmedizin Berlin, Körperschaft des öffentlichen Rechts Metamizolderivate zur Prävention und Therapie der pulmonalen Hypertonie
CN113636977B (zh) * 2021-09-01 2022-12-20 温州大学 2-芳基苯并氮杂卓及其衍生物的合成方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7354722B1 (en) * 1999-06-11 2008-04-08 Signal Pharmaceuticals Modulators of Smurf and BMP/TGFβ signaling pathways
WO2011151361A1 (en) * 2010-06-03 2011-12-08 Glaxo Group Limited Novel compounds

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2376675A1 (en) * 1999-06-11 2000-12-21 The Research Foundation Of State University Of New York Antagonists of bmp and tgf.beta. signalling pathways
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
GB0312368D0 (en) 2003-05-30 2003-07-02 Univ Aston Novel ureido- and amido-pyrazolone derivatives
EP1667983A4 (en) 2003-09-23 2010-07-21 Merck Sharp & Dohme PYRAZOL MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS
US7291743B2 (en) 2005-03-29 2007-11-06 Geneblue Corporation Isoxazole derivatives and methods of treating nitric oxide mediated diseases
BRPI0618079A2 (pt) * 2005-10-31 2011-08-16 Biolipox Ab composto ou um sal farmaceuticamente aceitável do mesmo, formulação farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, método de tratamento de uma doença, produto de combinação, e, processos para a preparação de um composto, de uma formulação farmacêutica, e de um produto de combinação
WO2008121861A2 (en) 2007-03-28 2008-10-09 Xenon Pharmaceuticals Inc. Pyrazole and pyrrole compounds useful in treating iron disorders
US20090069288A1 (en) 2007-07-16 2009-03-12 Breinlinger Eric C Novel therapeutic compounds
US8211927B2 (en) 2007-08-02 2012-07-03 MSD, Oss B.V. 5-phenyl-isoxazole-3-carboxamide derivatives as TRPV1 modulators
US8642660B2 (en) 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
US9403833B2 (en) 2014-05-14 2016-08-02 Novartis Ag Carboxamide derivatives
TW201946921A (zh) 2014-05-14 2019-12-16 瑞士商諾華公司 甲醯胺衍生物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7354722B1 (en) * 1999-06-11 2008-04-08 Signal Pharmaceuticals Modulators of Smurf and BMP/TGFβ signaling pathways
WO2011151361A1 (en) * 2010-06-03 2011-12-08 Glaxo Group Limited Novel compounds

Also Published As

Publication number Publication date
UY36123A (es) 2016-01-08
JP6587637B2 (ja) 2019-10-09
SG11201609311RA (en) 2016-12-29
EP3143014B1 (en) 2018-10-24
TN2016000491A1 (en) 2018-04-04
MX2016014946A (es) 2017-02-28
WO2015177646A1 (en) 2015-11-26
US9931319B2 (en) 2018-04-03
CN106536512B (zh) 2019-06-07
AR100439A1 (es) 2016-10-05
EP3143014A1 (en) 2017-03-22
CA2948582A1 (en) 2015-11-26
JP2017515845A (ja) 2017-06-15
AP2016009554A0 (en) 2016-11-30
KR20170003667A (ko) 2017-01-09
CN106536512A (zh) 2017-03-22
US20150329549A1 (en) 2015-11-19
US9403833B2 (en) 2016-08-02
EA201692298A1 (ru) 2017-03-31
US20170000770A1 (en) 2017-01-05
AU2015263049A1 (en) 2016-11-24
TW201623288A (zh) 2016-07-01

Similar Documents

Publication Publication Date Title
AU2015263049B2 (en) Carboxamide derivatives
US11672782B2 (en) Carboxamide derivatives
JP6403761B2 (ja) ピラゾロ−ピロリジン−４−オン誘導体および疾患の処置におけるその使用
TW201623285A (zh) 新穎雜芳基化合物及其作為藥物之用途
AU2017344489C1 (en) Naphthyridinone derivatives and their use in the treatment of arrhythmia
TW201720799A (zh) 新穎之經吡唑基取代之雜芳基化合物及其作為藥物之用途
WO2015173659A2 (en) Carboxamide derivatives
ES2707734T3 (es) Derivados de carboxamida
WO2015173656A1 (en) Carboxamide derivatives
HK40009292B (en) Naphthyridinone derivatives and their use in the treatment of arrhythmia
HK40009292A (en) Naphthyridinone derivatives and their use in the treatment of arrhythmia
HK1229326B (en) Carboxamide derivatives

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired